WO2001021137A8 - Extracts of orange peel for prevention and treatment of cancer - Google Patents

Extracts of orange peel for prevention and treatment of cancer

Info

Publication number
WO2001021137A8
WO2001021137A8 PCT/US2000/025733 US0025733W WO0121137A8 WO 2001021137 A8 WO2001021137 A8 WO 2001021137A8 US 0025733 W US0025733 W US 0025733W WO 0121137 A8 WO0121137 A8 WO 0121137A8
Authority
WO
WIPO (PCT)
Prior art keywords
orange peel
cancer
extracts
prevention
treatment
Prior art date
Application number
PCT/US2000/025733
Other languages
French (fr)
Other versions
WO2001021137A1 (en
Inventor
Geeta Ghai
Robert T Rosen
Chi-Tang Ho
Kuang Yu Chen
Nitin Telang
Martin Lipkin
Mou Tuan Huang
Charles Boyd
Katalin Csiszar
Original Assignee
Univ Rutgers
Geeta Ghai
Robert T Rosen
Ho Chi Tang
Kuang Yu Chen
Nitin Telang
Martin Lipkin
Mou Tuan Huang
Charles Boyd
Katalin Csiszar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers, Geeta Ghai, Robert T Rosen, Ho Chi Tang, Kuang Yu Chen, Nitin Telang, Martin Lipkin, Mou Tuan Huang, Charles Boyd, Katalin Csiszar filed Critical Univ Rutgers
Priority to AU73849/00A priority Critical patent/AU7384900A/en
Priority to JP2001524564A priority patent/JP2003509447A/en
Priority to US10/088,664 priority patent/US7201928B1/en
Priority to CA2383224A priority patent/CA2383224C/en
Priority to EP00961973A priority patent/EP1214040A4/en
Publication of WO2001021137A1 publication Critical patent/WO2001021137A1/en
Publication of WO2001021137A8 publication Critical patent/WO2001021137A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Compositions and methods of inhibiting tumor cell growth and treating and preventing cancer are provided based on administration of an orange peel extract either alone or in combination with other phytochemicals.
PCT/US2000/025733 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer WO2001021137A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU73849/00A AU7384900A (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer
JP2001524564A JP2003509447A (en) 1999-09-21 2000-09-20 Orange peel extract for cancer prevention and treatment
US10/088,664 US7201928B1 (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer
CA2383224A CA2383224C (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer
EP00961973A EP1214040A4 (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15501899P 1999-09-21 1999-09-21
US60/155,018 1999-09-21

Publications (2)

Publication Number Publication Date
WO2001021137A1 WO2001021137A1 (en) 2001-03-29
WO2001021137A8 true WO2001021137A8 (en) 2001-07-26

Family

ID=22553801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025733 WO2001021137A1 (en) 1999-09-21 2000-09-20 Extracts of orange peel for prevention and treatment of cancer

Country Status (5)

Country Link
EP (1) EP1214040A4 (en)
JP (1) JP2003509447A (en)
AU (1) AU7384900A (en)
CA (1) CA2383224C (en)
WO (1) WO2001021137A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100833805B1 (en) * 2000-04-19 2008-05-30 니치유 가부시키가이샤 Cosmetic composition
WO2002039956A2 (en) 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US7087790B2 (en) 2003-08-29 2006-08-08 Rutgers, The State University Of New Jersey Benzotropolone derivatives and modulation of inflammatory response
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20070042972A1 (en) * 2005-05-24 2007-02-22 Mckeever Kenneth H Compositions and methods for optimizing exercise recovery
WO2007135569A2 (en) * 2006-02-09 2007-11-29 Kgk Synergize Inc Methods of treating canine osteosarcoma
WO2008035208A2 (en) * 2006-05-19 2008-03-27 Kgk Synergize Inc The use of flavonoids for the inhibition of cellular growth
CN100422168C (en) * 2006-06-15 2008-10-01 中国科学技术大学 Hesperetin derivant and preparation process thereof
DE102007037772A1 (en) * 2007-08-10 2009-02-12 Csabai, Zsolt, Dr. Ph. Antioxidant complex based on Grape Vital (citrus and / or grape seed and / or flavonoid base)
JP5742050B2 (en) * 2011-03-01 2015-07-01 国立研究開発法人農業・食品産業技術総合研究機構 NK cell activator and NK cell activation method
WO2013172682A1 (en) 2012-05-16 2013-11-21 연세대학교 산학협력단 Use of flavone compound for prevention or treatment of obesity
SG11201804473RA (en) * 2015-12-07 2018-06-28 Univ Kyoto Pd-1 signal inhibitor combination therapy
CN115772145A (en) * 2022-11-29 2023-03-10 三峡大学 Citrus fruit extract and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824320A4 (en) * 1995-05-05 2000-06-07 Hauser Inc High purity carnosic acid from rosemary and sage extracts by ph-controlled precipitation
JPH09176009A (en) * 1995-12-27 1997-07-08 Inahata Koryo Kk New antimutagenic agent and substance having antimutagenic action
US5830738A (en) * 1996-06-04 1998-11-03 Clemson University Extraction of pigment from plant material
US6251400B1 (en) * 1997-09-26 2001-06-26 Kgk Synergize Inc Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
JP3571899B2 (en) * 1997-12-18 2004-09-29 小川香料株式会社 Flavor deterioration inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose

Also Published As

Publication number Publication date
JP2003509447A (en) 2003-03-11
CA2383224A1 (en) 2001-03-29
WO2001021137A1 (en) 2001-03-29
EP1214040A4 (en) 2004-06-23
CA2383224C (en) 2010-12-07
AU7384900A (en) 2001-04-24
EP1214040A1 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
WO2001021137A8 (en) Extracts of orange peel for prevention and treatment of cancer
WO2002047706A3 (en) Selective cox-2 inhibition from plant extracts
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001080870A3 (en) Compositions derived from cranberry and grapefruit and therapeutic uses therefor
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU1783800A (en) Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU4830097A (en) Use of an extract of Cimicifuga
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
WO2000047231A3 (en) Novel antisense inhibition of rad51
WO2001034131A3 (en) Combination chemotherapy
WO2001034135A3 (en) Oncolytic combinations for the treatment of cancer
WO2001064251A3 (en) Combination chemotherapy
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2001034133A3 (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 73849/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2383224

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 524564

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000961973

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000961973

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10088664

Country of ref document: US